Pediatric Nuclear Medicine & Dosing
Weight-based activity, dose optimization, and the child-specific study set
Quick Answer
Pediatric administered activity is weight-based and dose-optimized — the lowest activity that still yields a diagnostic study (ALARA). Two harmonized standards are used: the EANM Dosage Card and the North American consensus guidelines (the "Image Gently" pediatric framework). Certain studies dominate pediatric practice — DMSA and MAG3 (UTI/reflux, hydronephrosis), the milk scan (reflux), the Meckel scan, and bone scintigraphy — and children require attention to immobilization, sedation policy, and, for therapy, growth-adjusted approaches.
Why Children Are Different
Children are not small adults: higher radiosensitivity and longer life-expectancy raise the stochastic-risk stakes, lower body weight concentrates absorbed dose, and cooperation/motion and renal/hepatic maturity affect technique. Optimization means the lowest activity that still answers the question — never so low that a non-diagnostic study forces a repeat (adding dose and delay).
Dosing Frameworks
- EANM Dosage Card and North American consensus give per-kilogram (or body-metric) activities with minimum administered activities to preserve image quality; the two have been largely harmonized.
- Principle: scale to body size, respect a minimum diagnostic activity, and never sacrifice a diagnostic study by underdosing to non-diagnostic images.
The Pediatric Study Set (High-Yield)
| Study | Agent | Question |
|---|---|---|
| DMSA | Tc-99m-DMSA | Acute pyelonephritis; cortical scarring (UTI/reflux) |
| MAG3 ± furosemide | Tc-99m-MAG3 | Hydronephrosis, UPJ obstruction, split function |
| Milk scan | Tc-99m-sulfur colloid (labeled feed) | Gastroesophageal reflux; aspiration |
| Meckel scan | Tc-99m-pertechnetate | Ectopic gastric mucosa (painless lower-GI bleed) |
| Bone scintigraphy | Tc-99m-MDP | Occult/non-accidental trauma, osteomyelitis, back pain |
| MIBG | I-123-MIBG | Neuroblastoma (staging/response; theranostic gate) |
Practical Technique in Children
- Immobilization and distraction; sedation per institutional policy (with monitoring) when motion would ruin the study.
- Hydration and voiding for renal/pelvic studies; feeding schedules for the milk scan.
- Thyroid blockade for iodinated agents (MIBG, radioiodine).
- Age-appropriate consent/assent and caregiver counseling on radiation.
Therapy Considerations
- Radioiodine avoided under age 5; ages 5–10 use low, calculated activities.
- I-131-MIBG (neuroblastoma) and, more recently, Lu-177-DOTATATE (≥ 12 y) are delivered in specialized centers with growth-adjusted, dose-aware protocols.
- Lower body weight raises blood/marrow absorbed dose for the same activity — a therapy-planning consideration.
- A negative diagnostic whole-body scan does not exclude pulmonary metastases in a child.
Reporting / Practice Notes
- State the weight-based activity and framework (EANM/North American) used.
- Note sedation/immobilization and any technical limitations.
- For therapy, document growth-adjusted dosimetry considerations and specialized-center delivery.
Common Pitfalls
- Underdosing to a non-diagnostic study (repeat imaging adds dose and delay).
- Assuming adult protocols/precautions transfer directly to children.
- Neglecting thyroid blockade for iodinated agents or hydration/voiding for renal studies.
Board Pearls
Pediatric activity is weight-based and dose-optimized (ALARA), but the goal is the lowest activity that still yields a diagnostic study — with a minimum administered activity to preserve image quality. Under-dosing to a non-diagnostic study adds dose and delay by forcing a repeat. Use the harmonized EANM Dosage Card and North American consensus ("Image Gently") schemes.
A handful of studies dominate: DMSA (pyelonephritis/scarring), MAG3 ± furosemide (hydronephrosis/obstruction, split function), the milk scan (reflux/aspiration), Meckel (ectopic gastric mucosa), and bone scintigraphy (occult/non-accidental trauma, osteomyelitis) — plus MIBG for neuroblastoma.
Therapy caveats: radioiodine is avoided under age 5; I-131-MIBG and Lu-177-DOTATATE (≥ 12 y) are delivered in specialized centers; lower body weight raises blood/marrow absorbed dose; and a negative diagnostic scan does not exclude pulmonary metastases in a child. Technique matters — immobilization/sedation, hydration/voiding, thyroid blockade, and caregiver counseling.
Related Pages
- Related: DMSA cortical, renal scintigraphy, GI bleeding & Meckel, neuroblastoma, radiation biology & protection.
- Calculator: pediatric-dose tool; pitfalls: Pearls, pitfalls & normal variants.
Figure / Diagram Suggestions
- A weight-based dosing nomogram concept (per-kg with a minimum activity floor).
- The pediatric study set at a glance (agent → question).
- An optimize-don't-just-minimize graphic (diagnostic-quality floor).
Self-Check (Board-Style)
Q1. What is the guiding principle of pediatric administered activity, and why not simply minimize?
Answer: Weight-based, dose-optimized (ALARA) — the lowest activity that still yields a diagnostic study, with a minimum activity floor. Over-minimizing forces a non-diagnostic repeat, adding dose and delay.
Q2. Which two harmonized frameworks guide pediatric dosing?
Answer: The EANM Dosage Card and the North American consensus guidelines ("Image Gently").
Q3. Why does the same activity deliver a higher marrow dose in a small child?
Answer: Lower body weight concentrates absorbed dose — a key therapy-planning consideration (e.g. I-131-MIBG, Lu-177-DOTATATE).
Q4. A child's diagnostic MIBG scan is negative. Does this exclude pulmonary metastases?
Answer: No — a negative diagnostic whole-body scan does not exclude pulmonary metastases in a child; correlate with other imaging and post-therapy scans.
Evidence & sources
https://nuc.med/pediatric-nuclear-medicine/ Report an issue